FWP Forward Pharma ADS

Forward Pharma Announces Expected Delisting of its American Depositary Shares from the Nasdaq Capital Market

Forward Pharma Announces Expected Delisting of its American Depositary Shares from the Nasdaq Capital Market

COPENHAGEN, Denmark, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward”), today announced that that on December 16, 2022 it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying us that Nasdaq believes that Forward is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. We will not appeal this determination. Therefore, we expect the trading of our American Depositary Shares on The Nasdaq Capital Market to be suspended at the opening of business on December 28, 2022, and that Nasdaq will file a Form 25-NSE with the U.S. Securities and Exchange Commission (the “SEC”), which will remove Forward’s securities from listing and registration on The Nasdaq Stock Market. Additionally, we intend to file with the SEC a Form 15 requesting the suspension of Forward’s reporting obligations.

Forward Pharma A/S Investor Relations Contact:

Forward Pharma A/S

Claus Bo Svendsen, MD, PhD

Chief Executive Officer

Investor Relations

Forward Pharma A/S



EN
19/12/2022

Underlying

FWPForward Pharma ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Forward Pharma ADS

 PRESS RELEASE
Free
FWP Forward Pharma ...

Forward Pharma Announces Expected Delisting of its American Depositary...

Forward Pharma Announces Expected Delisting of its American Depositary Shares from the Nasdaq Capital Market COPENHAGEN, Denmark, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward”), today announced that that on December 16, 2022 it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying us that Nasdaq believes that Forward is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. We will not appeal this determination. Therefore, we expect the trading of our American D...

December 19, 2022 1 EN
 PRESS RELEASE
Free
FWP Forward Pharma ...

Forward Pharma Announces the Decision of the Enlarged Board of Appeal ...

Forward Pharma Announces the Decision of the Enlarged Board of Appeal of the European Patent Office in the EP2801355 Petition for Review COPENHAGEN, Denmark, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”), today announced that the Enlarged Board of Appeal (the “EBA”) of the European Patent Office (the “EPO”) has denied Forward’s petition for review (the “Petition”) of the decision of the Technical Board of Appeal of the EPO that confirmed the revocation of the EP2801355 patent by the EPO Opposition Division in the opposition proceeding (“Opp...

December 6, 2022 1 EN
 PRESS RELEASE
Free
FWP Forward Pharma ...

Forward Pharma Announces the Decision of the Technical Board of Appeal...

Forward Pharma Announces the Decision of the Technical Board of Appeal of the European Patent Office in the EP2801355 Appeal Hearing COPENHAGEN, Denmark, Sept. 06, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company”), today announced that the Technical Board of Appeal (the “TBA”) of the European Patent Office (the “EPO”) has dismissed Forward’s appeal of the previous decision of the EPO Opposition Division to revoke the EP2801355 patent (the “’355 patent”) following the oral hearing. The TBA made its decision after considering Forward’s appeal again...

September 6, 2021 1 EN
 PRESS RELEASE
Free
FWP Forward Pharma ...

Forward Pharma Reports Financial and Operational Results from the Year...

Forward Pharma Reports Financial and Operational Results from the Year Ended December 31, 2020 COPENHAGEN, Denmark, April 14, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial results for the year ended December 31, 2020. Our net loss for the year ended December 31, 2020 was $6.4 million, or $0.07 per share, versus a net loss of $4.2 million, or $0.04 per share for the year ended December 31, 2019. Our research and development and general and administrative cos...

April 14, 2021 1 EN
 PRESS RELEASE
Free
FWP Forward Pharma ...

Forward Pharma Announces Rescheduling of the EP2801355 Appeal Hearing ...

Forward Pharma Announces Rescheduling of the EP2801355 Appeal Hearing to September 6, 2021 due to COVID-19 Restrictions COPENHAGEN, Denmark, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company”), today announced that due to ongoing precautionary measures against the spread of the novel coronavirus (“COVID-19”), the Technical Board of Appeal (the “TBA”) of the European Patent Office (the “EPO”) again has rescheduled the oral hearing of the appeal against the decision of the Opposition Division that revoked the EP2801355 patent (the “’355 Paten...

January 12, 2021 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch